\n The U.S. International Trade Commission has declined Masimo’s request for a new import ban on Apple Watch models concerning the blood oxygen sensor. This decision marks a significant victory for Apple in a protracted patent dispute. <\/p>\n
USA – Ekhbary News Agency<\/p>\n
The U.S. International Trade Commission (ITC) has refused to impose a new import ban on Apple Watch devices, rejecting a request from Masimo related to its blood oxygen sensor technology. This ruling represents a major win for Apple in a legal battle that has spanned over six years. Masimo had accused Apple’s blood oxygen saturation (SpO2) sensor of infringing on its patents, leading to an import ban on certain Apple Watch models in 2023.<\/p>\n
Apple successfully navigated the ban by re-engineering the feature to process data on a paired iPhone. On Friday, the ITC confirmed that this redesigned Apple Watch does not infringe Masimo’s patents and declined to review a prior ruling. An Apple representative stated the company is grateful for the decision, ensuring continued availability of the vital health feature. While Masimo may still pursue further appeals, this ITC decision significantly bolsters Apple’s position in the ongoing intellectual property dispute.<\/p>\n